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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether sublingual
buprenorphine treatment is effective and efficient when compared to traditional neonatal opium
solution (morphine) in treating newborns with neonatal abstinence syndrome (NAS).
Study Design: Review of one randomized active-control clinical trial, one randomized doubleblind, double-dummy clinical trial, and one retrospective cohort analysis.
Data Sources: All articles were published in English between the years of 2011 and 2017.
Articles were obtained from peer-reviewed journals and databases using PubMed and Embase.
Outcomes: Outcomes measured were length of stay using the neonates birth date and hospital
discharge date as well as duration of treatment using the cessation date of treatment once
MOTHER NAS score <8.
Results: Kraft et al. (2011) found a statistically significant decrease in hospital stay and duration
of treatment with buprenorphine when compared to morphine treatment of NAS. Further study
by Kraft et al. (2017) again found a statistically significant decrease in hospital stay and duration
of treatment with buprenorphine compared to morphine. Hall et al. (2016) found in their
retrospective cohort study that patients treated with buprenorphine had a shorter hospital stay and
a shorter duration of treatment when compared to patients who were treated with morphine or
methadone.
Conclusions: All three studies confirm that buprenorphine treatment is both effective and
efficient when compared to traditional neonatal opium solution (morphine) in treating newborns
with neonatal abstinence syndrome. Further studies should place focus on treatment weaning the
mother from the offending substance and its effect on the incidence of NAS, length of stay in the
hospital, and possible elimination of pharmacologic intervention in neonates.
Keywords: neonatal abstinence syndrome, sublingual buprenorphine
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INTRODUCTION
Neonatal abstinence syndrome (NAS) occurs in newborns who were exposed to drugs in
utero and results in the presence of signs and symptoms of withdrawal. Presentation of NAS
includes tremors, irritability, high-pitched crying, increased muscle tone, vomiting, poor sleep,
diarrhea, tachypnea, sweating and low-grade fever. In addition to withdrawal, the newborns are
also at risk for poor intrauterine growth, premature birth, seizures, and birth defects. It is evident
that this is an unfortunate series of events and difficult way to begin life.
The current opioid crisis that has plagues adults in the US today has sadly affected the
neonate population as well. The incidence of NAS has significantly risen over the last 10 years,
with the number of neonates admitted to the NICU with NAS increasing 10-fold from 2005 to
2011.1 In 2009, NAS averaged $53,400 in hospital charges with an associated average hospital
stay of 16.4 days, whereas, uncomplicated births average $9,500 and 3.3 days in the hospital.2 A
recorded 9,674 neonates were kept in the hospital after birth for NAS in 2009.3
This influx in neonatal patients has put an extensive amount of stress on the
neonatologist’s workload. The high demand for specialized physicians, and the subsequent low
supply has provided a window of opportunity for physician assistants.4 With some additional
training, PAs can serve a vital role in the care of critically ill neonates and their families.4 They
have the ability to review labs, intubate neonates, accompany critical patients to procedures,
initiate treatment, and provide an integral role in providing direction and communication in
patient care.5
The exact pathophysiologic mechanism of opioid withdrawal in an infant is unknown.
However, it is known that the low molecular weight water-soluble opioids, as well as the
synthetic opiates, are easily able to cross the placenta and effect the fetus.1 The locus coeruleus
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of the pons is the most important and sensitive center in opioid withdrawal. Lack of opioids is
sensed, and an increased production of norepinephrine occurs, which causes many of the signs of
NAS.1
Treatment for NAS includes non-pharmacologic as well as pharmacologic regimens.
Non-pharmacologic therapies include swaddling, frequent feeds, pacifiers, music, and massage
therapy. Pharmacologic treatments consist of morphine, methadone, phenobarbital, clonidine,
and buprenorphine. Most treatment options for opioid withdrawal, as listed above, are for use in
adults. The standard of care for NAS has been morphine, but it has its own side effects and a
longer treatment duration. Buprenorphine has been routinely used in adults for abstinence
therapy and symptom control with lower rates of respiratory depression. This finding comes as a
highly attractive treatment option for neonates since NAS already puts a significant amount of
stress on the newborn.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not sublingual
buprenorphine treatment is effective and efficient when compared to traditional neonatal opium
solution (morphine) in treating newborns with neonatal abstinence syndrome (NAS).
METHODS
Two randomized control trials and one retrospective cohort analysis were selected for this
review. The population included newborns with neonatal abstinence syndrome with intervention
consisting of sublingual buprenorphine treatment. All three studies had a treatment group using
buprenorphine and an experimental group who received neonatal opium solution (morphine).
Outcomes measured were the efficacy of buprenorphine as measured by the duration of
treatment and the efficiency as measured by the length of stay in the hospital.
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Databases used to select adequate studies include PubMed and Embase. Keywords used
during the search were “neonatal abstinence syndrome” and “buprenorphine”. The three chosen
studies were written in English and published between the years 2011-2017. Inclusion criteria for
all three articles included randomized control trials and retrospective cohort analyses. Exclusion
criteria, which all studies abided by, included studies that contained neonates without NAS and
used methadone as the experimental therapy treatment. Table 1 displays detailed individual study
components as well as inclusion and exclusion criteria. Statistical analysis of data included the
mean change from baseline, median, confidence intervals, and p-values.
OUTCOMES MEASURED
This meta-review dissects the difference in length of stay in the hospital and the duration
of treatment when comparing buprenorphine and morphine as treatment options. Length of stay
was determined by the neonate’s discharge date compared to their birth date. Duration of
treatment was determined using the MOTHER NAS score. The MOTHER NAS score is a
variation of the Finnegan scoring instrument.6 The score ranges from 0 to 42, with the higher end
signifying a greater severity (Table 2).6 Cessation of treatment in patients was determined by a
MOTHER score of <8.
RESULTS
Kraft et al. (2011) ran a randomized, open-label, active-control clinical trial comparing
the standardized oral morphine to the experimental sublingual buprenorphine on 24 term infants
with NAS in need of pharmacologic treatment.3 Treatment was initiated in any full-term neonate
(≥37 weeks’ gestation) with a total MOTHER NAS score ≥24 after three consecutive counts, or a
single score of ≥12.3 Additional inclusion and exclusion criteria is indicated in Table 1.
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Table 1 – Demographics & Characteristics of Included Studies
Study
Type
#
Age
Inclusion Criteria
Pts
Kraft3
Active24 > 37
Infants with in
(2011) control RCT
weeks
utero exposure to
gestation opioids, requiring
pharmacologic
treatment for
NAS

Kraft6
(2017)

Doubleblind,
doubledummy RCT

63

> 37
Term infants
weeks
exposed to
gestation opioids in utero
with signs of
NAS.

4

Exclusion Criteria

W/D

Interventions

Exposure to
benzodiazepines,
maternal use of
alcohol, medical
illness, major
congenital
malformations, or
breastfed infants.

0

Sublingual
buprenorphine
15.9 mcg/kg in
3 doses;
Morphine 0.4
mg/kg/d in 6
doses; adjunct
Phenobarbital
therapy when
max dose of
Buprenorphine
(60 mcg/kg/d)
or Morphine (1
mg/kg/d) is
reached and
NAS not
controlled
Sublingual
buprenorphine
15.9 mcg/kg in
3 doses;
Morphine 0.4
mg/kg/d in 6
doses;
Phenobarbital
rescue dose
when max dose
of
Buprenorphine
(60 mcg/kg/d)
or Morphine (1
mg/kg/d) is
reached and
NAS not
controlled
Buprenorphine,
Methadone,
Methadone,
adjunct
phenobarbital
therapy.

Major congenital
malformations,
birth weight of
<2200g, a
medical/neurologic
illness,
hypoglycemia
requiring IV
glucose, bilirubin
level >20 mg/dL,
maternal use of a
benzodiazepine 30
days before birth,
or seizures.
Breastfeeding
exclusion criteria
amended during
study.
Hall7 Retrospective 360 >34
Infants treated
No infant had a
(2016)
Cohort
weeks
pharmacologically major congenital
Analysis
gestation for NAS with an
malformation or
opioid during the experienced
4-year period.
iatrogenic
withdrawal.

5

0
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Table 2 – MOTHER NAS Scale; Scored Elements6
Signs and Symptoms
Score
Crying: Excessive high pitched
2
Crying: Continuous high pitched
3
Sleeps <1 hour after feeding
3
Sleeps <2 hours after feeding
2
Sleeps <3 hours after feeding
1
Hyperactive Moro Reflex
1
Markedly Hyperactive Moro Reflex
2
Mild Tremors: Disturbed
1
Moderate-Severe Tremors: Undisturbed
2
Increased Muscle Tone
1-2
Excoriation
1-2
Generalized seizure (or convulsion)
8
Fever >37.3 C (99.2 F)
1
Sweating
1
Nasal Stuffiness
1
Frequent Yawning (≥4 successive times)
1
Sneezing (≥4 successive times)
1
Tachypnea (Respiratory Rate >60/min)
2
Poor feeding
2
Vomiting (or regurgitation)
2
Loose Stools
2
Failure to thrive (Current weight > 10%
2
below birth weight 90%) (record daily
weights)
Excessive irritability
1-3
Patients were randomized to traditional treatment of oral morphine and an experimental group of
sublingual buprenorphine with 12 participants in each group.3 This study adopted an intentionto-treat basis.3 Using their continuous data, they determined that buprenorphine treatment had
statistically significant improvements in both duration of treatment and length of hospital stay
(Table 3).
Table 3 – Outcomes of Buprenorphine and Morphine
Outcome
Buprenorphine (Mean ± SD)
Length of Stay
32 ± 24
Duration of Treatment 23 ± 12

Morphine (Mean ± SD)
42 ± 13
38 ± 14

P-value
0.05
0.01
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Expanding on their prior research, Kraft et al. (2017) took it upon themselves to perform
Wish a double-blind, double-dummy clinical trial.1 In this study, they had 63 full-term infants
(≥37 weeks’ gestation) randomly assigned to receive either sublingual buprenorphine or oral
morphine to treat their NAS.6 As with their previous study they used the same MOTHER NAS
score guidelines, three consecutive scores totaling ≥24 or one single score ≥12.6 Table 1 contains
additional inclusion and exclusion criteria for the study. Throughout their research, they lost 5
participants, 3 from the buprenorphine group and 2 from the morphine group, all who were
withdrawn by their parents due to concern for ineffective treatment.6 The 5 withdrawn patients
received open-label morphine due to the researchers following the intention-to-treat principle.6
Again the researchers further proved, with more reliable study design, that buprenorphine
therapy had a statistically significant improvement in shortening the duration of treatment and
the length of hospital stay (Table 4).
Table 4 - Outcomes of Buprenorphine and Morphine with P-value and 95% CI
Outcome
Buprenorphine Morphine
P-value
Difference
(median); N=33 (median); N=30
(95% CI)
Length of Stay
21 (7 to 71)
33 (18 to 70)
<0.001
-12 (-22 to -7)
Duration of
15 (3 to 67)
28 (13 to 67)
<0.001
-13 (-21 to -7)
Treatment
In a retrospective cohort analysis Hall et al. (2016) evaluated 360 infants treated for
neonatal abstinence syndrome over a four-year period.7 In June 2015, a standardized weaning
protocol was put in place with sublingual buprenorphine as standard treatment despite the type of
intrauterine opioid exposure.7 Detailed inclusion and exclusion criteria are shown in Table 1.
Overall, the study determined that neonates treated with buprenorphine treatment had a 3.0-day
reduction in treatment duration and a 2.8-day reduction in hospital stay (Table 5).7 Additionally,
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they were able to determine that buprenorphine treatment resulted in hospital discharge of infants
without need for adjunct therapy (p <0.001).7
Table 5 – Retrospective Analysis of Outcomes for Treatment with Buprenorphine vs. Morphine
Regardless of Intrauterine Exposure
Outcome
Buprenorphine,
Morphine,
P-value
Mean (95% CI); N=174
Mean (95% CI); N=186
Length of Stay
12.4 (11.3-13.6)
15.2 (14.1-16.4)
<0.001
Duration of Treatment 7.4 (6.3-8.5)
10.4 (9.3-11.5)
<0.001

DISCUSSION
The beginning of life for a neonate is stressful in the physiological sense. They have gone
from a protective, life-sustaining, and nutrient providing uterine environment to the open world.
Adding on additional stress from opioid withdrawal is the last thing a neonate needs to
overcome. That being said, all three of the studies in this evidence-based systematic review
demonstrate that treatment with buprenorphine allows for a shorter hospital stay and less time in
treatment. While buprenorphine has been proven effective, it comes with its short-comings.
In both Kraft et al. (2011, 2017) studies, it was noted that a few patients receiving
buprenorphine required supplemental treatment with phenobarbital to provide adequate disease
stability.3,6 It is unclear if the need for phenobarbital necessarily indicates treatment failure in the
infant population.3 Many factors go into neonatal withdrawal such as the type of abused agent
used, strength and quantity of offending agent, and duration of intrauterine exposure.8 With this
in mind, it is no question that an infant may require supplemental treatment for symptom control.
Another item to consider is the type of intrauterine drug exposure included in the study.
One might challenge the fact that both Kraft et al. (2011, 2017) studies excluded the use of
benzodiazepines (Table 1). However, it should be noted that the Hall et al. (2016) retrospective
study did not have any exclusion criteria for the offending agents and had the same significant
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results for both measured outcomes (Table 5). This finding should further suggest that even
when the type of intrauterine exposure was not controlled for, the outcome still presented
buprenorphine as the better treatment option.
Limitations to this particular systemic review include the fact that two of the chosen
studies were conducted by the same research group at the same hospital in Philadelphia, PA. It is
known that the second study expanded on the limitations that they discovered in their first study,
such as the number of participants and study control factors.3 After improving their parameters
and expanding their study size, they were still able to identify a positive outcome with
buprenorphine over morphine treatment.6 This duplication in research teams was recognized
during the study selection process and an attempt was made to further support the systematic
review by selecting a study from a different location, such as with Hall et al. (2016). In doing
this, however, the strength of a randomized control trial was sacrificed and thus replaced with a
retrospective cohort analysis.
CONCLUSION
This systemic review confirms that buprenorphine treatment is both effective and
efficient when compared to traditional neonatal opium solution (morphine) in treating newborns
with neonatal abstinence syndrome. Since the United States is undergoing such an epidemic
with opioid abuse and addiction in the adult population, it is important not to forget about others
that may subsequently suffer the consequence. These findings come at a crucial time for
neonates born to mothers who battle with addiction. Further studies should be recommended in
researching the safest amount of buprenorphine that a neonate can receive to try to limit or
eliminate the need for supplemental phenobarbital. Additionally, it might be beneficial to focus
on the mother and her access to adequate care both for prenatal and behavioral management.
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Perhaps a study could explore the effectiveness of weaning a mother off the offending agents
early in gestation and the resulting incidence in NAS, length of hospital stay, or if it omits a need
for pharmacologic treatment altogether.

REFERENCES
1. Prabhakar Kocherlakota. Neonatal abstinence syndrome. Pediatrics.
2014;134(2):e547. https://search.proquest.com/docview/1552145460.
2. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM.
Neonatal abstinence syndrome and associated health care expenditures: United states,
2000-2009. JAMA. 2012;307(18):1934-1940. http://dx.doi.org/10.1001/jama.2012.3951.
doi: 10.1001/jama.2012.3951.
3. Kraft WK, Dysart K, Greenspan JS, Gibson E, Kaltenbach K, Ehrlich ME. Revised dose
schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence
syndrome. Addiction. 2011;106(3):574580. http://onlinelibrary.wiley.com.ezproxy.pcom.edu:2048/doi/10.1111/j.13600443.2010.03170.x/abstract. doi: 10.1111/j.1360-0443.2010.03170.x.
4. Perman S. A day in the life. JAAPA: Official Journal of the American Academy of
Physician Assistants. 2009;22(8):15-16.
https://www.ncbi.nlm.nih.gov/pubmed/19725408. doi: 10.1097/01720610-20090800000005.
5. Eric W Reynolds, J Timothy Bricker. Nonphysician clinicians in the neonatal intensive
care unit: Meeting the needs of our smallest patients. Pediatrics. 2007;119(2):361-369.
doi: 10.1542/peds.2006-1084.
6. Kraft WK, Adeniyi-Jones S, Chervoneva I, et al. Buprenorphine for the treatment of the
neonatal abstinence syndrome. N Engl J Med. 2017;376(24):23412348. http://dx.doi.org.ezproxy.pcom.edu:2048/10.1056/NEJMoa1614835. doi:
10.1056/NEJMoa1614835.
7. Hall ES, Isemann BT, Wexelblatt SL, et al. A cohort comparison of buprenorphine versus
methadone treatment for Neonatal abstinence syndrome. The Journal of Pediatrics.
2016;170:44.e1. http://www.sciencedirect.com.ezproxy.pcom.edu:2048/science/article/pii
/S0022347615014511. doi: //doi-org.ezproxy.pcom.edu/10.1016/j.jpeds.2015.11.039.
8. Neonatal abstinence syndrome. Stanford Children's Health
Website. https://www.stanfordchildrens.org/en/topic/default?id=neonatal-abstinencesyndrome-90-P02387. Accessed 11/29/2018.

